Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (374) clinical trials

Tissue Blood and Body Fluid Sample Collection From Patients With Hematologic Cancer

OBJECTIVES Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies. Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies. Maintain responsible and ...

Phase N/A

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

PRIMARY OBJECTIVES: I. To determine the rate of conversion to full donor chimerism (FDC) following a post transplant infusion (day 30-60) of freshly enriched allogeneic CD8+ memory T-cells in patients with acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), or Hodgkin lymphoma (HL), who received non-myeloablative total ...

Phase

Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

The intensive chemotherapy (hyper-CVAD therapy) used in this study includes a combination of 8 chemotherapy drugs. These drugs include Adriamycin (doxorubicin), cyclophosphamide, cytarabine (Ara-C), dexamethasone, methotrexate, nelarabine, pegaspargase, and vincristine. The maintenance therapy used in this study includes a combination of 6 chemotherapy drugs. These drugs include pegaspargase, methotrexate, prednisone, ...

Phase

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Phase

B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression

B type chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the western world. It is a disease that occurs primarily in aging individuals and occurs more frequently in males than females. Although B-CLL was considered a homogeneous condition, recent studies by our laboratory and others suggest that B-CLL ...

Phase N/A

Unrelated Donor Stem Cell Transplantation

The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells from unrelated individuals or cord blood registries.

Phase N/A

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant. In addition, some patients who enroll to other CD19-CAR-T cell therapy trials might ...

Phase

Acalabrutinib in Patients With Relapsed/Refractory and Treatment na ve Deletion 17p CLL/SLL

To investigate the safety and efficacy of acalabrutinib for patients with CLL/SLL that have relapsed/refractory disease or treatment naive deletion 17p.

Phase

Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Primary objectives To determine the safety and feasibility of adoptive transfer of T cells modified to express CD19-specific chimeric antigen receptor (CD19CAR) for treatment of leukemia and lymphoma Secondary objectives To measure the efficacy of anti-tumor responses after CD19CAR T cell infusion To determine if CD19CAR T cells engineered with ...

Phase

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

PRIMARY OBJECTIVES: I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD20 vector (referred to as CART-20 cells). II. Determine duration of in vivo survival of CART-20 cells. RT-PCR analysis of whole blood will be used to detect and quantify survival of CART-20 ...

Phase